CAJ | 학술논문

目的：检测肾细胞癌患者癌组织中Periostin基因表达的改变，探讨其相关的临床意义。方法收集我院2012年12月至2014年3月泌尿外科收治的肾细胞癌患者64例，每例另取癌旁3 cm非癌肾组织作为对照。荧光定量PCR检测Periostin基因表达量。结果 Periostin基因在肾癌组织和癌旁正常肾组织中的表达量分别为0．318±0．076和0．142±0．043，癌旁组织中的表达量显著低于肾癌组织（t＝5．36，P＜0．01）。Periostin基因的表达量在不同的年龄、性别和病理类型之间无显著性差异（P＞0．05），高分化患者Periostin基因表达量为0．242±0．051显著低于中、低分化的0．358±0．086（t＝2．62，P＜0．05），无淋巴结转移患者Periostin基因表达量为0．257±0．057，显著低于有淋巴结转移的0．361±0．082（t＝2．51，P＜0．05），临床Ⅰ、Ⅱ期患者Periostin基因表达量为0．273±0．053，显著低于临床Ⅲ、Ⅳ期的0．354±0．079（t＝2．33，P＜0．05）。结论 Periostin基因的异常高表达参与了肾细胞癌的发生发展过程，有可能成为肾细胞癌分级以及预后评估的分子标记物。
목적：검측신세포암환자암조직중Periostin기인표체적개변，탐토기상관적림상의의。방법수집아원2012년12월지2014년3월비뇨외과수치적신세포암환자64례，매례령취암방3 cm비암신조직작위대조。형광정량PCR검측Periostin기인표체량。결과 Periostin기인재신암조직화암방정상신조직중적표체량분별위0．318±0．076화0．142±0．043，암방조직중적표체량현저저우신암조직（t＝5．36，P＜0．01）。Periostin기인적표체량재불동적년령、성별화병리류형지간무현저성차이（P＞0．05），고분화환자Periostin기인표체량위0．242±0．051현저저우중、저분화적0．358±0．086（t＝2．62，P＜0．05），무림파결전이환자Periostin기인표체량위0．257±0．057，현저저우유림파결전이적0．361±0．082（t＝2．51，P＜0．05），림상Ⅰ、Ⅱ기환자Periostin기인표체량위0．273±0．053，현저저우림상Ⅲ、Ⅳ기적0．354±0．079（t＝2．33，P＜0．05）。결론 Periostin기인적이상고표체삼여료신세포암적발생발전과정，유가능성위신세포암분급이급예후평고적분자표기물。
ABSTRACT:Objective To detect the mRNA expression of Periostin in renal cell carcinoma and to explore its clinical sig‐nificance .Methods A total of 64 patients with renal cell carcinoma treated in our hospital during Dec .2012 and March 2014 were enrolled in this study .The adjacent healthy tissues of each case served as controls .The mRNA expression of Periostin was detected with Real‐time PCR .Results The mRNA expression of Periostin in renal cell carcinoma was 0 .318 ± 0 .076 ,which was significantly higher than that in the healthy tissues (0 .142 ± 0 .043) ,(t=5 .36 ,P<0 .01) .There was no difference be‐tween patients with different gender ,age ,and pathological type (P>0 .05) .The mRNA expression of Periostin in well differ‐entiation group was 0 .242 ± 0 .051 ,lower than that in median and low differentiation group (0 .358 ± 0 .086) ,( t=2 .62 , P<0.05) .The mRNA expression of Periostin in non‐lymph node metastasis group was 0 .257 ± 0 .057 ,lower than that in lymph node metastasis group (0 .361 ± 0 .082) ,(t=2 .33 ,P<0 .05) .The mRNA expression of Periostin in stage I and II group was 0 .273 ± 0 .053 ,lower than that in stage Ⅲ and Ⅳ group (0 .354 ± 0 .078) ,(t=2 .33 ,P<0 .05) .Conclusion The upregula‐tion of Periostin is involved in the occurrence and development of renal cell carcinoma ,which can be used as a biomarker to es‐timate the differentiation and prognosis of renal cell carcinoma .